Biomolecules, Vol. 15, Pages 1574: Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure

Biomolecules, Vol. 15, Pages 1574: Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure Biomolecules doi: 10.3390/biom15111574 Authors: Simone Pasquale Crispino Annunziata Nusca Aurora Ferro Riccardo Cricco Martina Ciancio Andrea Segreti Ilaria Cavallari Mario Sabatino Luciano Potena Gian Paolo Ussia Francesco Grigioni Glucagon-like peptide-1 receptor […]

Genes, Vol. 16, Pages 1352: GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways

Genes, Vol. 16, Pages 1352: GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways Genes doi: 10.3390/genes16111352 Authors: Daniela Lucente Stefania Bellino Anna La Salvia Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed to treat type 2 diabetes mellitus, are now being investigated as agents in oncology. Recent preclinical […]

Why this leading fundie is tipping ResMed shares for near-term gains

ResMed Inc (ASX: RMD) shares are marching higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) sleep disorder treatment company closed on Friday trading for $38.32. In morning trade on Monday, shares are swapping hands for $38.58 each, up 0.7%. For some context, the ASX 200 is up 0.3% at this same time. Taking a […]

3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs

Key Points Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer’s drug, Kisunla, has blockbuster potential, and if efforts at early detection are successful, it could have even more upside. The company hopes that by using artificial intelligence (AI), it can accelerate drug development. 10 […]

America’s obesity crisis meets the Ozempic boom as data reveals GLP-1 hot spots

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon surge even higher — a trend already spreading unevenly across the U.S., with some states seeing greater uptick than others. Based on insurance claims data from Purple Lab, a […]